The prostacyclin pathway in pulmonary arterial hypertension: a clinical review

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System

(2016) Robert C. Bourge et al.   CHEST

Novel Strategies in the Treatment of Pulmonary Arterial Hypertension

(2016) Rosalinda Madonna et al.   CURRENT DRUG TARGETS

Selexipag for the treatment of pulmonary arterial hypertension

(2016) Manuel Jonas Richter et al.   EXPERT OPINION ON PHARMACOTHERAPY

Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension

(2016) Satoshi Akagi et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Treatment of pulmonary hypertension

(2016) Marius M Hoeper et al.   Lancet Respiratory Medicine

An Observational Study of Inhaled-Treprostinil Respiratory-Related Safety in Patients with Pulmonary Arterial Hypertension

(2016) R. T. Zamanian et al.   Pulmonary Circulation

Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era

(2016) Bradley A. Maron et al.   JAMA Cardiology

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry

(2015) Harrison W. Farber et al.   CHEST

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2015) Nazzareno Galiè et al.   EUROPEAN RESPIRATORY JOURNAL

Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension

(2015) Tomoaki Ishihara et al.   JOURNAL OF CONTROLLED RELEASE

Management of Pulmonary Arterial Hypertension

(2015) Vallerie V. McLaughlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Selexipag for the Treatment of Pulmonary Arterial Hypertension

(2015) Olivier Sitbon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

(2015) Nazzareno Galiè et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro and In Vivo Performance of a Pre-Filled, Electrochemically-Actuated Infusion System

(2015) Assaf Shaked et al.   PHARMACEUTICAL RESEARCH

The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors

(2015) Lucie H. Clapp et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Inhaled Therapies for Pulmonary Hypertension

(2015) N. S. Hill et al.   Respiratory Care

The molecular targets of approved treatments for pulmonary arterial hypertension

(2015) Marc Humbert et al.   THORAX

Long-Term Therapy with Oral Treprostinil in Pulmonary Arterial Hypertension Failed to Lead to Improvement in Important Physiologic Measures: Results from a Single Center

(2015) Kelly Marie Chin et al.   Pulmonary Circulation

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

(2014) Darren B. Taichman et al.   CHEST

Long-term Survival of Japanese Patients with Pulmonary Arterial Hypertension Treated with Beraprost Sodium, an Oral Prostacyclin Analogue

(2014) Seiichiro Sakao et al.   INTERNAL MEDICINE

Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry

(2014) Pavel Jansa et al.   BMC Pulmonary Medicine

Subcutaneous Treprostinil is Well Tolerated with Infrequent Site Changes and Analgesics

(2014) R. James White et al.   Pulmonary Circulation

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension

(2013) Olivier Sitbon et al.   AMERICAN HEART JOURNAL

Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension

(2013) Gérald Simonneau   ANNALS OF INTERNAL MEDICINE

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study)

(2013) Victor F. Tapson et al.   CHEST

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension

(2013) Zhi-Cheng Jing et al.   CIRCULATION

One-year experience with intravenous treprostinil for pulmonary arterial hypertension

(2013) Raymond L. Benza et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry

(2013) Harrison W. Farber et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pulmonary Arterial Hypertension

(2013) Michael D. McGoon et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Clinical Classification of Pulmonary Hypertension

(2013) Gerald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pulmonary Hypertension in Portugal: First Data from a Nationwide Registry

(2013) Rui Baptista et al.   Biomed Research International

Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension

(2012) Yi Ling et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

(2012) Brendan J. Whittle et al.   BIOCHEMICAL PHARMACOLOGY

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study)

(2012) Victor F. Tapson et al.   CHEST

Predicting survival in pulmonary arterial hypertension in the UK

(2012) Wai-Ting Nicola Lee et al.   EUROPEAN RESPIRATORY JOURNAL

Survival in pulmonary hypertension in Spain: insights from the Spanish registry

(2012) Pilar Escribano-Subias et al.   EUROPEAN RESPIRATORY JOURNAL

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

(2012) Gérald Simonneau et al.   EUROPEAN RESPIRATORY JOURNAL

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry

(2012) Marius M. Hoeper et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension

(2012) Michael D. McGoon et al.   MAYO CLINIC PROCEEDINGS

Bloodstream Infections in Patients With Pulmonary Arterial Hypertension Treated With Intravenous Prostanoids: Insights From the REVEAL REGISTRY®

(2012) Natalie Kitterman et al.   MAYO CLINIC PROCEEDINGS

Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era

(2011) Rui Zhang et al.   CHEST

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension

(2011) Raymond L. Benza et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy

(2011) Lars Knudsen et al.   BMC Pulmonary Medicine

Survival in Pulmonary Arterial Hypertension: A Brief Review of Registry Data

(2011) Sunil Pauwaa et al.   Pulmonary Circulation

The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States

(2010) Adaani E. Frost et al.   CHEST

Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

(2010) Marc Humbert et al.   CIRCULATION

Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension

(2010) Vallerie V. McLaughlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension

(2010) Frank Reichenberger et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Long-term therapy with inhaled iloprost in patients with pulmonary hypertension

(2010) Horst Olschewski et al.   RESPIRATORY MEDICINE

Pulmonary Arterial Hypertension

(2009) David B. Badesch et al.   CHEST

Long-term outcome with intravenous iloprost in pulmonary arterial hypertension

(2009) M. M. Hoeper et al.   EUROPEAN RESPIRATORY JOURNAL

Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial

(2009) Jagdish Hiremath et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol

(2009) D. B. BADESCH et al.   JOURNAL OF RHEUMATOLOGY

A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2- -N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form,  acetic Acid (MRE-269), on Rat Pulmonary Artery

(2008) K. Kuwano et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS